Drugs / PERTUZUMAB ZUVOTOLIMOD
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04460456 | Jul 2020 → Dec 2022 | HER2 positive breast carcinoma | Silverback Therapeutics | Unknown | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05091528 | Feb → Jul 2022 | HER2 positive breast carcinoma, non-small cell lung carcinoma | Silverback Therapeutics | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PERTUZUMAB ZUVOTOLIMOD | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095143 ↗ |
| Known as | SBT6050 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05091528 ↗ |
| Route | Subcutaneous | “Dose range of 0.45 to 0.6 mg/kg by subcutaneous (SC) injection” NCT05091528 ↗ |